Livact Indications/Uses

Improves hypoalbuminemia in patients with decompensated hepatic cirrhosis presenting with hypoalbuminemia despite adequate dietary intake.
Livact is indicated for use in patients presenting with hypoalbuminemia despite adequate dietary intake or in whom total dietary calories and protein (amino acids) intake is restricted due to complicated diabetes mellitus or hepatic encephalopathy, among patients with decompensated hepatic cirrhosis presenting with hypoalbuminemia as indicated by a serum albumin level of ≤3.5 g/dL with current or a history of ascites/edema or hepatic encephalopathy. A dietetic instruction should be provided to the patient in case of dietary deficiency despite the patient being amply capable of food ingestion in the absence of diabetes mellitus and hepatic encephalopathy. If the patient is deficient in dietary intake due to development of hepatic encephalopathy, a drug containing calories and protein (amino acids) should be administered.
Livact should not be administered to the following patients with markedly advanced hepatic cirrhosis since such patients may not respond to Livact therapy: Patients with stage III or more in the severity of coma due to hepatic encephalopathy.
Patients with a total bilirubin level of ≥3 mg/dL.
Patients with a markedly depressed hepatic function for protein synthesis.